featured
HRQoL in HR+/HER2− Advanced Breast Cancer Patients Treated With Abemaciclib + Fulvestrant After Endocrine Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Health-Related Quality of Life in MONARCH 2: Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy
Oncologist 2019 Oct 24;[EPub Ahead of Print], PA Kaufman, M Toi, P Neven, J Sohn, EM Grischke, V Andre, C Stoffregen, S Shekarriz, GL Price, GC Carter, GW SledgeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.